Rachel Haurwitz is the president and CEO of Caribou Biosciences, a CRISPR genome editing company she co-founded in 2011 with Nobel Prize winner Jennifer Doudna and other CRISPR scientists. Caribou is a clinical-stage company developing an internal pipeline of off-the-shelf genome-edited CAR-T and CAR-NK cell therapies for oncology. In 2014, Rachel was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. She serves on the board of directors of the Biotechnology Organization (BIO). Rachel earned an A.B. in Biological Sciences from Harvard College and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.